Assessing the potential of rementinib for COVID-19 pneumonia
First written in FY2020. 3 of 7 entries say "Restated". Latest entry: FY2022-Q2.
No other company in this theme has enough history to compare yet.
- FY2022-Q2AdvancedAnnual report
「In an LPS-induced acute inflammatory pneumonia model, administration of letermovir resulted in a trend toward reductions in pulmonary cytokine levels and inflammatory cell counts, providing results suggestive of its efficacy against the heightened acute inflammation associated with COVID-19. In addition, in a parabiosis mouse model, it was shown that mesenchymal stem cells induced by letermovir differentiated into Ace2-positive type 2 alveolar epithelial cells in the injured lungs and contributed to the regeneration of alveolar function.」
Regarding the potential use of letermovir for lung diseases, including COVID-19 pneumonia, a trend toward reductions in cytokine levels and inflammatory cell counts was confirmed in an acute inflammatory pneumonia model, while differentiation of induced stem cells into alveolar epithelial cells and their contribution to the regeneration of alveolar function were demonstrated in a parabiosis mouse model. - FY2022-Q1AdvancedAnnual report
「In a mouse model of pulmonary fibrosis, administration of letermovir statistically significantly suppressed hydroxyproline levels, an indicator of collagen in the lungs, by up to 70%, and histopathological evaluation confirmed a reduction in the fibrosis score. In addition, measurements of percutaneous arterial oxygen saturation (SpO2) confirmed a trend toward improved pulmonary function, resulting in improvements on pulmonary function tests, which are important in clinical practice.」
Regarding the potential use of letermovir for pulmonary fibrosis and COVID-19 pneumonia, hydroxyproline levels were suppressed by up to 70% in a pulmonary fibrosis model, and a trend toward improved pulmonary function was confirmed through SpO2 measurements. - FY2021AdvancedAnnual report
「In a mouse model of pulmonary fibrosis, administration of letermovir statistically significantly suppressed hydroxyproline levels, an indicator of collagen in the lungs, by up to 70%, and histopathological evaluation confirmed a reduction in the fibrosis score.」
Regarding the potential use of letermovir for sequelae from COVID-19 pneumonia, hydroxyproline levels were suppressed by up to 70% in a pulmonary fibrosis model, and a reduction in the fibrosis score was confirmed. - FY2021-Q3RestatedAnnual report
「Mesenchymal stem cells that accumulate in injured tissue from the bone marrow following administration of letermovir have been shown to exert anti-inflammatory and anti-fibrotic effects, as well as regenerate epithelial and vascular tissue. Accordingly, letermovir is expected to become the world's first treatment to reduce the risk of sequelae from COVID-19 pneumonia.」
The potential use of letermovir to reduce the risk of sequelae from COVID-19 pneumonia and its mechanism of action have been reconfirmed. - FY2021-Q2RestatedAnnual report
「Mesenchymal stem cells that accumulate in injured tissue from the bone marrow following administration of letermovir have been shown to exert anti-inflammatory and anti-fibrotic effects, as well as regenerate epithelial and vascular tissue. Accordingly, letermovir is expected to become the world's first treatment to reduce the risk of sequelae from COVID-19 pneumonia.」
The potential use of letermovir to reduce the risk of sequelae from COVID-19 pneumonia and its mechanism of action have been reconfirmed. - FY2021-Q1RestatedAnnual report
「Mesenchymal stem cells that accumulate in injured tissue from the bone marrow following administration of letermovir have been shown to exert anti-inflammatory and anti-fibrotic effects, as well as regenerate epithelial and vascular tissue. Accordingly, letermovir is expected to become the world's first treatment to reduce the risk of sequelae from COVID-19 pneumonia.」
The potential use of letermovir to reduce the risk of sequelae from COVID-19 pneumonia and its mechanism of action have been reconfirmed. - FY2020First statedAnnual report
「The Company considers it a social mission to deliver regenerative medicine products that reduce the risk of sequelae to patients suffering from COVID-19 pneumonia worldwide. Through joint research with Osaka University, we are conducting preclinical studies of letermovir and seeking to accelerate the evaluation of its efficacy against COVID-19 pneumonia, with the aim of initiating clinical trials in patients with COVID-19 pneumonia as soon as possible.」
The Company first stated its policy of advancing efficacy evaluations for COVID-19 pneumonia through preclinical studies conducted as part of joint research with Osaka University, with the aim of initiating clinical trials. The project has also been selected for an AMED program.